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Is FGF21 a good drug candidate for
diabetes, dyslipidemia, and/or obe-
sity? The favorable diabetes and lipid
phenotypes are encouraging. The
rhesus studies (Kharitonenkov et al.,
2007) suggest that these effects are
not rodent specific (for example, due
to the higher rodent liver PPARa levels
or the importance of active brown adi-
pose tissue). On the safety front, the
lack of detected hypoglycemia or cell
proliferation is important. Thus, this
mechanism seems worthy of further
investigation.
The observations reported in this
issue by Badman et al. (2007) and In-
agaki et al. (2007) identify FGF21 as
an important endocrine hormone
helping control adaptation to the
fasted state. This provides a previ-
ously missing link, downstream of
PPARa, by which the liver communi-
cates with the rest of the body in
regulating the biology of energy ho-
meostasis.
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Dietary restriction provides considerable health benefits and may even increase life span in humans.
Panowski et al. (2007) have now identified PHA-4/FoxA as an essential and specific component of
DR-induced life-span extension in C. elegans.The notion that life span is subject to
the action of genes has becomewidely
accepted. Despite the claims of popu-
lar anti-aging pills and creams, dietary
restriction (DR) or calorie restriction is
the only general nongenetic interven-
tion that has been shown to improve
health and increase life span in various
model systems. DR differs from star-
vation and is usually defined as about
30% lower food intake than that of ad
libitum feeding. In addition to DR, life
span can be extended by reduced in-
sulin/IGF-1 signaling (IIS) and reducedmitochondrial electron transport chain
activity (ECT) (Figure 1) (reviewed in
Wolff and Dillin, 2006).
A recent study by Panowski et al.
(2007) now identifies the C. elegans
pha-4 gene as an essential and unique
mediator of DR-induced life-span
extension. The Dillin lab previously
identified suppressor of MEK1 (SMK-
1) as a regulator of DAF-16, a forkhead
transcription factor homologous to
mammalian FoxO that mediates IIS-
induced longevity (Wolff et al., 2006).
However, the role of DAF-16 in DRCell Metabolhas remained enigmatic thus far, and
surprisingly, it was observed that
SMK-1, but not DAF-16, affected DR-
induced life span. Because DR uncou-
ples SMK-1 from DAF-16, the authors
hypothesized that SMK-1 could regu-
late another forkhead transcription
factor. By systematic screening of all
15 C. elegans forkheads, they identi-
fied PHA-4, the homolog of mamma-
lian FoxA (HNF-3). Two independent
DR models were used to demonstrate
PHA-4 involvement. The classical ge-
netic model for DR uses the mutantism 5, June 2007 ª2007 Elsevier Inc. 407
Cell Metabolism
Previewsworm eat-2(ad1116), which ex-
hibits reduced food intake due
to a pharyngeal pumping de-
fect. eat-2 worms lost their
usual life-span extension when
PHA-4 was depleted through
RNAi. The second, nongenetic
model involves ad libitum feed-
ing of worms in limiting dilu-
tions of bacteria. Extremes of
bacterial concentrations pro-
duce short-lived worms,
whereas conditions of optimal
food intake result in life-span
extension, termed bacterial
DR; this, however, was not the
case for pha-4 mutant worms.
PHA-4 not only mediates DR
but also appears to be specific
to DR. The long-lived daf-2mu-
tants could not be rescued by
pha-4 RNAi, in contrast to daf-
16 RNAi. Also, life span of
long-lived ECT mutants (cyc-1
or isp-1) was not decreased
by pha-4 RNAi. These observa-
tions show that pha-4 is specif-
ically required for DR-induced
life-span extension and also
that pha-4 RNAi does not in-
duce general sickness in
worms, thereby reducing life
span.
Since both PHA-4 and FoxA
play a role in development, it
was important to separate de-
velopmental effects from those
of life span. Thus, Panowski
et al. (2007) applied pha-4
RNAi at the adult stage only or
induced adult-specific loss of
pha-4 using temperature-sen-
sitive alleles. Both approaches
showed that PHA-4 affects life
span independently of its de-
velopmental function. DR in-
duces FoxA (Wolfrum et al.,
2004) and PHA-4 expression.
Therefore, the authors gener-
ated transgenic pha-4 worms
to analyze whether PHA-4 is
sufficient for life-span extension.
Intriguingly, only in the background of
daf-16 null mutants did pha-4 overex-
pression induce longevity, suggesting
that pha-4 and daf-16, although clearly
in separate genetic pathways, could
be partially redundant. This idea is
supported by the fact that both mam-
malian FoxA and FoxO regulate gluco-
neogenic genes such as PEPCK and
G6P.
Of the three mammalian FoxA
isoforms FoxA1, FoxA2, and FoxA3,
FoxA2 is regulated by the insulin/
PKB/AKT signaling axis, similar to
FoxO, the human homolog of DAF-
16. PKB/AKT phosphorylation
results in nuclear exclusion
and inhibition of FoxA2 tran-
scriptional activity (Wolfrum
et al., 2004). This regulation is
specific to FoxA2, as FoxA1
and FoxA3 lack PKB/AKT
phosphorylation sites. Thus, it
remains possible that in mam-
mals, crosstalk between IIS
and DR exists at the level of
FoxA2. On a similar note, mam-
malian target of rapamycin
(mTOR), a key player in nutrient
sensing, also acts downstream
of IIS, and it has been shown
that mTOR depletion extends
life span of Drosophila and C.
elegans in a DAF-16-indepen-
dent manner, reminiscent of
DR (Vellai et al., 2003). Thus, it
would be interesting to see
whether IIS may crosstalk to
PHA-4 through mTOR.
Yeast SIR2, a member of the
sirtuin family (SIRTs) of deace-
tylases, was the first gene
identified in regulation of DR
(Guarente and Picard, 2005).
Surprisingly, life-span exten-
sion by SIR2.1 overexpression
in C. elegans requires DAF-16
(Lin et al., 2002), which would
be at odds with the lack of
DAF-16 involvement in DR. In
contrast, resveratrol, an activa-
tor of SIRTs, increases life span
in a DAF-16-independent man-
ner (Viswanathan et al., 2005).
This pathway could potentially
involve PHA-4, and it would
be interesting to see whether
PHA-4 is potentially deacety-
lated by SIRTs (Figure 1). How
SIRTs discriminate between
acting on DAF-16/FoxO and/
or PHA-4/FoxA following DR
and resveratrol remains to be
established, but differential
sensitivity toward upstream
signals as shown for IIS regula-
tion of FoxA and FoxO could be
a possibility (Wolfrum et al., 2004).
The ‘‘free radical theory’’ proposes
aging to be the consequence of accu-
mulating damage caused by reactive
oxygen species (ROS). Thus, in the
simplest deduction, lowering ROS
reduces damage and consequently
Figure 1. Mechanisms of Life Span
Three main pathways of aging have now been identified: DR
(blue box and arrows), IIS (gray box and arrows), and ECT
(orange box and arrows). DR and IIS signal to members of
the forkhead transcription factor family (PHA-4/FoxA and
DAF-16/FoxO, respectively). The deacetylase SIR2 regulates
DAF-16 and has been shown to deacetylate FoxO. Because
DR requires both PHA-4/FoxA and SIR2, the possibility exists
that SIR2 also deacetylates PHA-4/FoxA (indicated by dashed
line and question mark). PKB/AKT has been shown to regulate
both FoxO and FoxA2 and may represent a specific point of
crosstalk between DR and IIS in mammalian cells. Further-
more, mTOR may similarly crosstalk with DR or signal directly
to mitochondria. PHA-4/FoxA and DAF-16/FoxO alter glucose
and lipid metabolism, thereby shifting mitochondrial activity. It
is suggested now that this may induce differential SOD ex-
pression and, in conjunction with altered metabolism, may be
responsible for life-span extension. ECT may proceed along
a type of retrograde pathway in which directly altered
mitochondrial activity results in changed ROS metabolism
and, consequently, differential regulation of SODs and altered
glucose and lipid metabolism (dashed orange arrows).408 Cell Metabolism 5, June 2007 ª2007 Elsevier Inc.
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some controversies exist, especially
with respect to the relationship be-
tween altered metabolism and ROS
generation, many studies indeed
establish a correlation between ROS
and life span. C. elegans expresses
five genes encoding superoxide dis-
mutases (SODs), which convert super-
oxide into peroxide, and of these,
sod-3 mediates IIS-induced life-span
extension. Interestingly, Panowski
et al. (2007) observe differential SOD
regulation by DR and IIS. DR specifi-
cally regulates sod-2 and -4, and this
is PHA-4 dependent, whereas IIS
specifically regulates sod-3, which is
DAF-16 dependent. Regulation of
sod-1 and -5 is common to both DR
and IIS. Since SODs probably show
cell-type-specific expression and are
also differentially localized within cells,
this differential SOD increase by DR as
compared to IIS indicates different
locations and/or mechanisms of ROS
generation following DR or IIS. There-
fore, it can be concluded that altered
metabolism toward mitochondrial res-
piration following DR (Lin et al., 2002)
or lowered IIS requires a change in
stressmaintenancebut that themolec-
ular components thereof depend on
the nature of the metabolic switch.
This illustrates that stress regulation is
not an independent trait for life-span
regulation but rather a sine qua non
and therefore intricately linked to spe-
cific metabolic shifts causing life-spanextension. Indeed, MnSOD mimetics
do not extend life span of otherwise
wild-type C. elegans (Keaney et al.,
2004). This further implies that, since
different stressmaintenanceprograms
combine with different life-span inter-
ventions, the full range of different
stress-resistance phenotypes (thermo-
tolerance, paraquat, DNA damage
etc.) will be not always be observed in
long-lived animals. Multiple examples
exist of long-lived C. elegans that do
not show resistance to all types of
exogenous stresses (reviewed in Wolff
and Dillin, 2006). Consequently, it is
unlikely that one unified downstream
genetic program exists that conveys
life-span extension for DR, IIS, and
altered mitochondrial activity.
Finally, in mammalian cells, exoge-
nous stress increases expression of
SODs, underlining their role in altered
stress conditions. However, this also
illustrates that ROS not only is a dam-
age factor in aging but also has
a signaling function. Peroxide gener-
ated by SODs, although potentially
damaging, can also act as a signaling
molecule due to its relative long half-
life. Consistent with this, DAF-16/
FoxO regulation by the peroxide-regu-
lated stress kinase JNK extends life
span in C. elegans and Drosophila
(Oh et al., 2005; Wang et al., 2005).
Thus, life-span extension may depend
not only on lowered ROS but also on
the signaling ability of ROS. Under-
standing the metabolic and ROS re-Cell Metaboquirements by which PHA-4 regulates
life span will eventually bring us closer
to a central question in aging research:
If we wish, can we extend our own
lives?
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